Abstract
Cognitive deficits are now recognized widely as core features of schizophrenia, and as major contributors to the clinical outcome of the disorder. They are also studied widely as ‘endophenotypes’, reflecting a growing consensus that schizophrenia is a broader, more multidimensional illness than the diagnostic criteria required for its formal diagnosis. This evolving view of cognition underlies its utilization in recent initiatives for intervention and assessment in schizophrenia. Two of these initiatives are reviewed in this paper. The first focuses on the development and validation of the MATRICS Cognitive Consensus Battery, a standardized battery of neuropsychological tests developed to assess the effectiveness of cognitive enhancing treatments in schizophrenia. A part of this effort includes the identification of performance-based, ‘co-primary’ measures of functional capacity that are related to cognition, and that are likely to show improvement at least partly as a function of improved cognition. The second initiative involves efforts to utilize neuropsychological deficits in the identification, validation and remediation of a liability syndrome for schizophrenia (‘schizotaxia’). The discussion of this effort focuses on the development of a syndrome that is both measurable and meaningful clinically, and that may provide useful intervention targets. The utilization of cognition in both of these initiatives underscores its functional importance in the clinical outcome of schizophrenia. Moreover, it helps to illuminate indicators of liability for schizophrenia that might be amenable to remediation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Gottesman I I, Hanson D R. Human development: Biological and genetic processes. Annu Rev Psychol, 2005, 56: 263–286
Harrison P J, Weinberger D R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry, 2005, 10: 40–68
Allan C L, Cardno A G, McGuffin P. Schizophrenia: From genes to phenes to disease. Curr Psychiatry Rep, 2008, 10: 339–343
Craddock N, O’Donovan M C, Owen M J. Psychosis genetics: Modeling the relationship between schizophrenia, bipolar disorder and mixed (or “schizoaffective”) psychoses. Schizophr Bull, 2009, 35: 482–490
Tsuang M T, Stone W S, Faraone S V. Towards reformulating the diagnosis of schizophrenia. Am J Psychiatry, 2000, 147: 1041–1050
Gottesman I I, Gould T D. The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry, 2003, 160, 636–645
Gur R E, Calkins M E, Gur R C, et al. The Consortium on the Genetics of Schizophrenia (COGS): Neurocognitive endophenotypes. Schizophr Bull, 2007, 33: 49–68
Turetsky B I, Calkins M E, Light G A, et al. Neurophysiological endophenotypes of schizophrenia: The viability of selected candidate measures. Schizophr Bull, 2007, 33: 69–94
Chan R C, Gottesman I I. Neurological soft signs as candidate endophenotypes for schizophrenia: A shooting star or a Northern star? Neurosci Biobehav Rev, 2008, 32: 951–957
Allen A J, Griss M E, Folley B S, et al. Endophenotypes in schizo phrenia: A selective review. Schizophr Res, 2009, 109: 24–37
Eack S M, Merman D E, Montrose D M, et al. Social cognition deficits among individuals at familial high risk for schizophrenia. Schizophr Bull, 2010, 36: 1081–1088
Braff D L, Freedman R. The importance of endophenotypes in studies of the genetics of schizophrenia. In: Davis K L, Charney D, Coyle J T, et al., eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Wilkins, 2002. 703–716
Braff D L, Freedman R, Shork N J, et al. Deconstructing schizophrenia: An overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull, 2007, 33: 21–32
Greenwood T A, Braff D L, Cadenhead K S, et al. The Consortium on the Genetics of Schizophrenia (COGS): Preliminary heritability analyses of endophenotypic measures for schizophrenia. Arch Gen Psychiatry, 2007, 64: 1242–1250
Husted J A, Lim S, Chow E W, et al. Heritability of neurocognitive traits in familial schizophrenia. Am J Med Gen (Neuropsychiatric Gen), 2009, 150B: 845–853
Faraone S V, Seidman L J, Kremen W S, et al. Structural brain abnormalities among relatives of patients with schizophrenia: Implications for linkage studies. Schizophr Res, 2003, 60: 125–140
Seidman L J, Wencel H E. Genetically mediated brain abnormalities in schizophrenia. Curr Psychiatry Rep, 2003, 5: 135–144
Gottesman I I, Shields J. Schizophrenia and Genetics: A Twin Study Vantage Point. New York: Academic Press, 1972
Tsuang M T. Genetics, epidemiology and the search for the causes of schizophrenia. Am J Psychiatry, 1994, 151: 3–6
Faraone S V, Kremen W S, Lyons M J, et al. Diagnostic accuracy and linkage analysis: How useful are schizophrenia spectrum phenotypes? Am J Psychiatry, 1995, 152: 1286–1290
Faraone S V, Seidman L J, Kremen W S, et al. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: A diagnostic efficiency analysis. J Abnormal Psychol, 1995, 104: 286–304
Woodberry K A, Giuliano A J, Seidman L J. Premorbid IQ in schizophrenia: A meta-analytic review. Am J Psychiatry, 2008, 165: 579–587
Mesholam-Gately R, Giuliano A J, Faraone S V, et al. Neurocognition in first-episode schizophrenia: A meta-analytic review. Neuropsychologia, 2009, 23: 315–336
Heinrichs R W, Zakzanis K K. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychologia, 1998, 12: 426–445
Gur R E, Nimgaonkar V L, Almasy L, et al. Neurocognitive endophenotypes in a multiplex multidimensional family study of schizophrenia. Am J Psychiatry, 2007, 164: 813–819
Green M F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry, 1996, 153: 321–330
Green M F, Kern R S, Braff D L, et al. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the “right stuff”? Schizophr Bull, 2000, 26: 119–136
Goldberg T E, David A, Gold J M. Neurocognitive impairments in schizophrenia: Their character and role in symptom formation. In: Weinberger D R, Harrison P J, eds. Schizophrenia. Oxford: Wiley-Blackwell, 2011. 142–162
Nuechterlein K H, Green M F, Kern R S, et al. The MATRICS consensus cognitive battery. Part 1: Test selection, reliability, and validity. Am J Psychiatry, 2008, 165: 203–213
Kern R S, Nuechterlein K H, Green M F, et al. The MATRICS Consensus cognitive battery. Part 2: Co-norming and standardization. Am J Psychiatry, 2008, 165: 214–220
Kern R S, Green M F, Nuechterlein K H, et al. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res, 2004, 72: 11–19
Dickinson D, Iannone V N, Wilk C M, et al. General and specific cognitive deficits in schizophrenia. Biol Psychiatry, 2004, 55: 826–833
Dickinson D, Ragland J D, Gold J M, et al. General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiatry, 2008, 64: 823–827
Dickinson D, Ragland J D, Calkins M E, et al. A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr Res, 2006, 85: 20–29
Wang Q, Vassos E, Deng W, et al. Factor structures of the neurocognitive assessments and familial analysis in first-episode schizophrenia patients, their relatives and controls. Aust N Z J Psychiatry, 2010, 44: 109–119
Nuechterlein K H, Barch D M, Gold J M, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res, 2004, 72: 29–39
Binder L M, Iverson G L, Brooks B L. To err is human: “Abnormal” neuropsychological scores and variability are common in healthy adults. Arch Clin Neuropsychol, 2009, 24: 31–46
Wechsler D. WAIS-III WMS-III Technical Manual. San Antonio: The Psychological Corporation: Harcourt Brace and Company, 1997
Squire L R, Shimamura A. The neuropsychology of memory dysfunction and its assessment. In: Grant I, Adams K M, eds. Neuropsychological Assessment of Neuropsychiatric Disorders. Oxford: Oxford University Press, 1996. 232–262
Fitch K, Bernstein S J, Aguilar M D, et al. The RAND/UCLA Appropriateness Method User’s Manual. Santa Monica, California: RAND, 2001
Nuechterlein K H, Green M F. MATRICS Consensus Cognitive Battery. Los Angeles: MATRICS Assessment, Inc, 2006
Kern R S, Gold J M, Dickinson D, et al. The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study. Schizophr Res, 2011, 126: 124–131
Harvey P D, Green M F, Nuechterlein K H. Latest developments in the MATRICS process. Psychiatry, 2010, 7: 49–52
Keefe R S, Fox K H, Harvey P D, et al. Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res, 2011, 125: 161–168
Buchanan R W, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull, 2005, 31: 5–19
Green M F, Nuechterlein K H, Kern R S, et al. Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS psychometric and standardization study. Am J Psychiatry, 2008, 165: 221–228
Green M F, Schooler N R, Kern R S, et al. Evaluation of co-primary measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry, 2011, 168: 400–407
Silverstein S M, Jaeger J, Donovan-Lepore A M, et al. A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries. J Clin Exp Neuropsychol, 2010, 32: 937–952
Barnett J H, Robbins T W, Leeson V C, et al. Assessing cognitive function in clinical trials of schizophrenia. Neurosci Biobehav Rev, 2010, 34: 1161–1177
Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press, 1911/1950
Gottesman I I. Schizophrenia Genesis: The Origin of Madness. New York: Freeman, 1991
Tsuang M T, Stone W S, Faraone S V. Schizophrenia: A review of genetic studies. Harv Rev Psychiatry, 1999, 7: 185–207
Glatt S J, Faraone S V, Tsuang M T. Genetic risk factors for mental disorders: General principles and state of the science. In: Tsuang M T, Stone W S, Lyons M J, eds. Recognition and Prevention of Major Mental and Substance Use Disorders. Washington D.C.: American Psychiatric Publishing, Inc, 2007. 3–20
Kendler K S. Twin studies of psychiatric illness: An update. Arch Gen Psychiatry, 2001, 58: 1005–1014
Rado S. Dynamics and clssification of disordered behavior. Am J Psychiatry, 1953, 110: 406–416
Rado S. Theory and therapy: The theory of schizotypal organization and its application to the treatment of decompensated schizotypal behavior. In: Scher S C, Davis H R, eds. The Outpatient Treatment of Schizophrenia. New York: Grune & Stratton, 1960. 87–101
Meehl P E. Schizotaxia, schizotypy, schizophrenia. Am Psychol, 1962, 17: 827–838
Meehl P E. Schizotaxia revisited. Arch Gen Psychiatry, 1989, 46: 935–944
Faraone S V, Green A I, Seidman L J, et al. “Schizotaxia”: Clinical implications and new directions for research. Schizophr Bull, 2001, 27: 1–18
Thaker G K. Endophenotypic studies in schizophrenia: Promises and challenges. Schizophr Bull, 2007, 33: 1–2
Stone W S, Faraone S V, Seidman L J, et al. Searching for the liability to schizophrenia: Concepts and methods underlying genetic high-risk studies of adolescents. J Child Adolesc Psychopharmacol, 2005, 15: 403–417
Tsuang M T, Stone W S, Auster T L. Prevention of schizophrenia. Expert Rev Neurotherapeutics, 2010, 10: 1165–1174
Dazzan P, Kravariti E, Fearon P, et al. Is the development of schizophrenia predictable? In: Stone W S, Faraone S V, Tsuang M T, eds. Early Clinical Intervention and Prevention in Schizophrenia. Totowa, New Jersey: Humana Press, 2004. 225–252
Cannon T D, Cadenhead K S, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: A multisite longitudinal study in North America. Arch Gen Psychiatry, 2008, 65: 28–37
Simon, A E, Roth B, Zmilacher S, et al. Developing services for the early detection of psychosis: A critical consideration of the current state of the art. Eur Child Adolesc Psychiatry, 2007, 16: 96–103
Simon A E, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. Schizophr Res, 2010, 116: 168–172
Erlenmeyer-Kimling L. Early neurobehavioral deficits as phenotypic indicators of the schizophrenia genotype and predictors of later psychosis. Am J Med Genet (Neuropsychiatric Genet), 2001, 105: 23–24
Mortensen P B, Pedersen M G, Pedersen C B. Psychiatric family history and schizophrenia risk in Denmark: Which mental disorders are relevant? Psychol Med, 2010, 40: 201–210
Tsuang M T, Stone W S, Seidman L J, et al. Treatment of nonpsychotic relatives of patients with schizophrenia: Four case studies. Biol Psychiatry, 1999, 41: 1412–1418
Tsuang M T, Gilbertson M W, Faraone S V. Genetic transmission of negative and positive symptoms in the biological relatives of schizophrenics. In: Marneros A, Tsuang M T, Andreasen N, eds. Positive vs. Negative Schizophrenia. New York: Springer-Verlag, 1991. 265–291
Tsuang M T, Stone W S, Tarbox S I, et al. An integration of schizophrenia with schizotypy: Identification of schizotaxia and implications for research on treatment and prevention. Schizophr Res, 2002, 54: 169–175
Snitz B E, MacDonald III A W, Carter A S. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: A meta-analytic review of putative endophenotypes. Schizophr Bull, 2006, 32: 179–194
Sitskoorn M M, Aleman A, Ebisch S J H, et al. Cognitive deficits in relatives of patients with schizophrenia: A meta-analysis. Schizophr Res, 2004, 71: 285–295
Kremen W S, Seidman L J, Pepple J R, et al. Neuropsychological risk indicators for schizophrenia: A review of family studies. Schizophr Bull, 1994, 20: 103–119
Chan R C K, Stone W S, Hsi X. Neurological and neuropsychological endophenotypes in schizophrenia spectrum disorders. In: Ritsner M S, ed. Textbook of Schizophrenia Spectrum Disorders. Volume II: Phenotypic and Endophenotypic Presentation. Heidleberg: Springer, 2011. 325–349
Stone W S, Faraone S V, Seidman L J, et al. Concurrent validation of schizotaxia: A pilot study. Biol Psychiatry, 2001, 50: 434–440
Weissman M M, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry, 1976, 33: 1111–1115
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed. Washington DC: American Psychiatric Association, 1994
Derogatis L R. Symptom Checklist-90-R (SCL-90-R). Minneapolis, MN: Computer Systems, Inc, 1993
Andreasen N C. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: The University of Iowa, 1983
Stone W S, Seidman L J. Towards a model of memory enhancement in schizophrenia: Glucose administration and hippocampal function. Schizophr Bull, 2008, 34: 93–108
Harvey P D. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev, 2009, 19: 324–335
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Stone, W.S., Hsi, X. Recent developments in neuropsychological endophenotypes for schizophrenia: Development of the MATRICS battery, liability syndromes and the near future. Chin. Sci. Bull. 56, 3385–3393 (2011). https://doi.org/10.1007/s11434-011-4759-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-011-4759-6